Plant & Quality
研究與發展Research & Development
High Barrier Generics
新聞發佈News & Media
/ Press Releases
TWi Biotechnology Receives Orphan Drug Designation for its Lead Drug Candidate AC-201 in United States.
TWi Pharmaceuticals Receives US FDA Final Approval on Generic Megestrol Acetate 125mg/ml Oral Suspension
TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 in United States.
Twi Pharmaceuticals, Inc. announces the acquisition of Hainan Visum Pharmaceutical Co., Ltd in China, starting the new chapter of international mergers and acquisitions.
TWi Announces Settlement of Lidoderm® Patent Litigation
©Copyright 2013 安成國際藥業股份有限公司版權所有